echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Wei Mi group is virtuous and thinks flying, helping Jun Qingtian to embrace the bright moon - a review of hot topics in the endocrine field of "Vi Mi Club"

    Wei Mi group is virtuous and thinks flying, helping Jun Qingtian to embrace the bright moon - a review of hot topics in the endocrine field of "Vi Mi Club"

    • Last Update: 2022-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    For medical professionals only for reference Endocrine is related to children's growth, development, metabolic stability and coordination of human body functions, and is an important foundation for children's healthy growth
    .

    If children's endocrine dysfunction is not treated in time, it will not only affect the child's physical development, but also adversely affect their mental health and life>
    .

    In order to promote academic exchanges on the cutting-edge progress of children's endocrine diseases, help improve the level of endocrine disease diagnosis and treatment, and allow more patients to benefit from the advancement of technology and concepts, Weisheng Pharmaceutical (Shanghai) has launched the "Vimbi Club - Weisheng Endocrine Peak".
    Forum"
    .

    From March 28th to April 1st, the first "Vitamin Fair" was held in the form of an online cloud
    .

    This summit forum focused on five hot topics in the endocrine field, growth hormone deficiency (GHD), achondroplasia (ACH), hypoparathyroidism (HP), obesity, and type 1 diabetes (T1DM).
    Experts and scholars in the field of external endocrinology brought in-depth interpretations and participated in thematic discussions
    .

    This conference has a strong lineup of experts, including Professor Fu Junfen from Children's Hospital Affiliated to Zhejiang University, Professor Luo Xiaoping from Tongji Hospital Affiliated to Huazhong University of Science and Technology, Professor Gu Xuefan from Xinhua Hospital Affiliated to Shanghai Jiaotong University, Professor Xia Weibo from Peking Union Medical College Hospital, Professor Gong Chunxiu from Beijing Children's Hospital of Capital Medical University, and Professor Gong Chunxiu from Beijing Children's Hospital of Capital Medical University.
    Professor Luo Feihong from the Pediatric Hospital of the University co-chaired the conference, and nearly 30 well-known experts at home and abroad attended the exchange
    .

    The conference week was held for 5 consecutive days.
    Top experts in different fields of endocrinology at home and abroad gathered online to share topics, and had lively discussions on the difficulties of clinical diagnosis and treatment and the latest progress.
    The conference was full of wonderful content, with a total of 5,793 online viewers
    .

    Dialogue between children and adults experts to jointly explore the optimal management of growth hormone deficiency.
    On the opening day of the conference, Professor Gong Chunxiu of Beijing Children's Hospital of Capital Medical University explained the clinical needs of LAGH research and development from the research and development history of long-acting growth hormone (LAGH).
    Deficiency disorder (PGHD), we also need to focus on treatment compliance
    .

    Authoritative organizations at home and abroad believe that the research and development of LAGH meets the clinical needs and achieves good clinical efficacy while maintaining safety
    .

    Speaker: Professor Chunxiu Gong, Professor Bradley S.
    Miller of the University of Minnesota School of Medicine, shared the research progress and new evidence of LAGH at the conference
    .

    He mentioned that TransCon hGH dosing once a week improves overall treatment effect by improving compliance, increasing serum IGF-1 levels and metabolism
    .

    Phase III clinical trial data show that TransCon hGH can effectively improve long-term height outcomes in children with PGHD
    .

    Speaker: Prof.
    Bradley S.
    Miller With the deepening understanding of growth hormone deficiency (GHD), the transitional growth hormone deficiency (TGHD) from late adolescence to adulthood has attracted the attention of clinicians
    .

    Professor Chen Xiaobo of Children's Hospital Affiliated to Capital Institute of Pediatrics talked with Professor Zhu Huijuan of Peking Union Medical College Hospital to discuss the whole-process management of GHD from the perspectives of pediatricians and adult endocrinologists
    .

    Professor Chen Xiaobo systematically explained the management of TGHD and emphasized the importance of recombinant human growth hormone (rhGH) in long-term treatment
    .

    TGHD patients who discontinue rhGH may develop a series of complications, such as impaired muscle development, significantly increased fat content, significantly reduced bone mineral density, and abnormal blood lipid profile.
    Continued use of rhGH replacement therapy should be considered
    .

    Speaker: Prof.
    Chen Xiaobo Prof.
    Zhu Huijuan introduced the clinical characteristics of adult growth hormone deficiency (AGHD) patients, and analyzed the differences in treatment goals between AGHD and PGHD patients in detail, and reminded clinicians to pay attention to the treatment of TGHD
    .

    According to domestic and foreign guidelines and consensus recommendations, rhGH can not only be used for PGHD to promote the linear growth of children, but also maintain the normal composition of TGHD patients and the balance of glucose and lipid metabolism in adulthood, improve the clinical symptoms of AGHD patients and reduce complications
    .

    Speaker: Prof.
    Zhu Huijuan The topic discussion session was chaired by Prof.
    Luo Xiaoping.
    Prof.
    Fu Junfen, Prof.
    Gong Chunxiu, Prof.
    Chen Xiaobo, Prof.
    Zhu Huijuan, Prof.
    Zhu Min from Children's Hospital of Chongqing Medical University, and Prof.
    Chen Linqi from Suzhou Children's Hospital participated in the discussion and discussed the whole process of GHD intensely.
    Pain points in management, actively share clinical countermeasures, and look forward to the application prospects of LAGH
    .

    The latest research shows that treating achondroplasia is no longer a dream.
    In 2021, China released the first "Expert Consensus on ACH Diagnosis and Treatment", filling the gap in the diagnosis and treatment of achondroplasia
    .

    On the second day of the meeting, as one of the main framers of the consensus, Professor Yu Yongguo from Xinhua Hospital Affiliated to Shanghai Jiaotong University explained the changes of ACH guidelines and consensus in recent years, and then discussed the diagnostic criteria, prenatal screening, clinical management and treatment.
    , interprets the key updates of the "Expert Consensus on Diagnosis and Treatment of ACH"
    .

    Speaker: Prof.
    Yu Yongguo, Guangzhou Children's Hospital Prof.
    Liu Li, introduced a national multi-center registry study among ACH patients, which integrated the demographic and clinical characteristics, growth and development criteria, Data on comorbidities, current status of diagnosis and medical intervention, and health-related quality of life will help improve domestic ACH epidemiological data, and help ACH patients be diagnosed, treatable, and accessible to medicines
    .

    Speaker: Prof.
    Li Liu, Dr.
    Irving Melita presented the latest diagnosis and treatment progress of ACH and analyzed the important role of fibroblast growth factor receptor 3 (FGFR3) in the treatment of ACH
    .

    Previous studies have shown that C-type natriuretic peptide (CNP) promotes endochondral bone formation by downregulating FGFR3 signaling and forms a targeted therapy
    .

    In this regard, he said that Vosoritide, a CNP analog, was the first drug approved by the U.
    S.
    Food and Drug Administration (FDA) and the European Union for ACH pediatric patients, which was a major breakthrough in the treatment of ACH
    .

    Speaker: Dr.
    Irving Melita At the end of this theme session, Professor Gu Xuefan moderated the discussion
    .

    Regarding the topic of whether there is an optimal treatment time window and treatment cycle for ACH, Prof.
    Yu Yongguo, Prof.
    Liu Li, Prof.
    Zhang Zhixin from China-Japan Friendship Hospital, and Prof.
    Li Cong from Shanghai Children's Hospital respectively expressed their views on the approved and under-study treatments.
    The prospect of drugs for achondroplasia has expressed expectations
    .
    Breakthrough of difficulties ,
    innovative solutions bring new ideas to hypoparathyroidism He mentioned that the efficacy and safety of existing parathyroid hormone replacement therapy programs are not satisfactory, and domestic and foreign guidelines recommend it only as a "supplementary" program when traditional treatment is difficult to control .
    The phase III clinical study data of the long-acting preparation TransCon PTH showed that it can significantly improve the quality of life of patients, and the safety is well tolerated .
    Speaker: Professor Xie Zhongjian currently has little epidemiological evidence on chronic HP, especially for the Chinese population .
    Professor Wu Yangfeng of Peking University Clinical Research Institute announced an ongoing research design on the current status of HP diagnosis and treatment in China at the meeting.
    It will provide an important reference for the country to formulate relevant guidelines and policies for the diagnosis and treatment of rare diseases . Speakers: Professor Wu Yangfeng After the keynote speech, Professor Xia Weibo invited the experts to discuss the existing problems in the management of HP.
    Professor Xie Zhongjian, Professor Wu Yangfeng, Professor Shan Zhongyan of the First Affiliated Hospital of China Medical University, Sun Yixian of Sun Yat-sen University Professor Yan Li from Memorial Hospital expressed his opinions respectively
    .

    Haitang, the patient representative, said that if the ideal hormone replacement therapy becomes possible, it will bring long-term benefits to many HP patients
    .

    On the fourth day of the conference to further explore the standardized management plan of childhood obesity, Professor Gong Chunxiu from Beijing Children's Hospital Affiliated to Capital Medical University introduced the clinical differential diagnosis of different diseases that cause obesity, and shared different prevention and treatment plans.
    Applicable situation, and finally shared the practical application of obesity management through a case, reminding pediatricians to pay attention to the supervision and management role of parents when treating childhood obesity, so as to help children develop a healthy life>
    .

    Speaker: Prof.
    Gong Chunxiu Prof.
    Wu Wei from Children's Hospital Affiliated to Zhejiang University mainly explained two rare diseases of obesity - Alstrom syndrome (AS) and Bardet-Biedl syndrome (BBS)
    .

    She mentioned that multidisciplinary comprehensive management is the future development direction of obesity syndrome, and the approval of drugs for the treatment of rare hereditary obesity will bring light to patients
    .

    Speaker: Professor Wu Wei Professor Chen Lulu of Wuhan Union Medical College Hospital pointed out that in recent years, the overweight and obesity rates of different age groups, genders and regions in China have been on the rise, increasing the risk of diabetes, coronary heart disease and other diseases
    .

    She listed the current status of clinical application of obesity treatment methods including life>
    .

    Speaker: Professor Chen Lulu and Professor Chen Wei of Peking Union Medical College Hospital shared the management strategies of childhood obesity in terms of life>
    .

    And emphasized the importance of medical nutrition weight loss in the entire obesity diagnosis and treatment process
    .

    Speakers: Prof.
    Chen Wei, Prof.
    Gong Chunxiu, Prof.
    Chen Lulu, Prof.
    Chen Wei, and Prof.
    Wu Wei analyzed the causes of childhood/adolescent obesity in China, and answered the strategies for childhood obesity management from the perspectives of life management and drug treatment.
    It is pointed out that there are many differences in the management goals and measures between adults and children in this treatment method
    .

    Time flies by revealing the direction of prevention and treatment of type 1 diabetes in children.
    At the end of the meeting, Professor Feihong Luo from the Pediatric Hospital Affiliated to Fudan University shared the diagnosis and treatment of T1DM in children
    .

    Professor Luo Feihong pointed out that T1DM in Chinese children has the phenomenon of rapid increase, younger age, and poor long-term blood sugar control
    .

    In this situation, comprehensive treatment is the basis of childhood diabetes
    .

    For the clinical management and treatment of T1DM in children and adolescents, he introduced the individualized control of blood sugar in detail, and proposed that artificial pancreas, immunotherapy and other directions will fundamentally change the treatment of T1DM
    .

    Speaker: Prof.
    Luo Feihong Prof.
    Francisco Leon focused on the role of the anti-CD3 monoclonal antibody Teplizumab in the delay and treatment of early clinical T1DM
    .

    He cited the PROTECT Phase III study, At-Risk study and other clinical research data, which confirmed that Teplizumab can significantly stabilize the C-peptide level and reverse/increase in subjects, that is, protect the recovery of pancreatic β-cell function in patients with T1DM, and in the future more value in the screening and early diagnosis of diseases
    .

    Speaker: Prof.
    Francisco Leon Under the chairmanship of Prof.
    Zhou Zhiguang from Xiang Er Hospital of Central South University, the meeting entered the thematic discussion session
    .

    For the differential diagnosis of T1DM and type 2 diabetes (T2DM) in children and adolescents, Professor Yang Tao from the First Affiliated Hospital of Nanjing Medical University, Professor Li Guimei from Shandong Provincial Hospital, Professor Cheng Xinran from Chengdu Women and Children's Central Hospital, and Professor Francisco Leon shared their experiences.
    Guidance strategies for patients transitioning from paediatric to adult treatment were exchanged
    .

    The conference summarized and reviewed the conference.
    Many experts and scholars shared and exchanged the latest diagnosis and treatment progress and clinical experience, and looked forward to the future development of the endocrine field in China
    .

    As Mr.
    Lu Anbang mentioned in his speech at the beginning of the meeting, the Weixi Summit Forum is a dialogue platform for Chinese and foreign experts and scholars, and an academic feast held by Weisheng Pharmaceuticals and experts and scholars in the field of endocrinology
    .

    For innovative pharmaceutical companies, solving the problem of endocrine diseases is not only about treating the disease, but also about treating the patient, so as to achieve better results in a more convenient and acceptable way for the patient
    .

    It is believed that with the development of the times and breakthroughs in clinical technology, new technologies, new concepts, and new drugs will continue to emerge, which will bring better clinical benefits to endocrine patients in China, and promote the level of diagnosis and treatment in China to a new level
    .

    For more exciting content of the conference, scan the QR code below to watch the replay👇👇👇code: VS-MA-ENDOSUMMIT-2022-010 Copyright Notice: This information is intended to help medical and health professionals better understand the latest developments in the field of related diseases
    .

    If copyright issues are involved, please contact us, and we will deal with it as soon as possible
    .

    For informational use by healthcare professionals only
    .

    Such information is not intended to replace professional medical advice in any way and should not be considered medical advice
    .

    If such information is used for purposes other than understanding information, this site and the author do not assume relevant responsibilities
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.